Standout Papers

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade 2016 2026 2019 2022 3.1k
  1. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade (2018)
    Michael A. Postow, Robert Sidlow et al. New England Journal of Medicine
  2. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2018)
    David Planchard, Sanjay Popat et al. Annals of Oncology
  3. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer (2018)
    Kathryn C. Arbour, Laura Mezquita et al. Journal of Clinical Oncology
  4. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study (2016)
    Matthew D. Hellmann, Naiyer A. Rizvi et al. The Lancet Oncology
  5. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer (2018)
    Matthew D. Hellmann, Margaret K. Callahan et al. Cancer Cell
  6. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer (2018)
    Lisa Derosa, Matthew D. Hellmann et al. Annals of Oncology
  7. Chromatin states define tumour-specific T cell dysfunction and reprogramming (2017)
    Mary Philip, Lauren Fairchild et al. Nature
  8. Acquired Resistance to Immune Checkpoint Inhibitors (2020)
    Adam J. Schoenfeld, Matthew D. Hellmann Cancer Cell
  9. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study (2018)
    Scott Gettinger, Leora Horn et al. Journal of Clinical Oncology
  10. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer (2016)
    Juan C. Osorio, Ai Ni et al. Annals of Oncology
  11. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy (2017)
    Marta Łuksza, Nadeem Riaz et al. Nature
  12. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint (2014)
    Matthew D. Hellmann, Jamie E. Chaft et al. The Lancet Oncology
  13. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2016)
    Scott Gettinger, Naiyer A. Rizvi et al. Journal of Clinical Oncology
  14. Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2016)
    Naiyer A. Rizvi, Matthew D. Hellmann et al. Journal of Clinical Oncology
  15. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib (2019)
    Adam J. Schoenfeld, Kathryn C. Arbour et al. Annals of Oncology

Immediate Impact

9 by Nobel laureates 15 from Science/Nature 121 standout
Sub-graph 1 of 19

Citing Papers

Neuronal substance P drives metastasis through an extracellular RNA–TLR7 axis
2024 StandoutNature
Principles and therapeutic applications of adaptive immunity
2024 Standout

Works of Matthew D. Hellmann being referenced

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade
2019
Chromatin states define tumour-specific T cell dysfunction and reprogramming
2017 StandoutNature

Author Peers

Author Last Decade Papers Cites
Matthew D. Hellmann 15902 8768 2648 4812 230 20.6k
Martin Reck 17003 13355 3125 2575 397 22.2k
Delvys Rodríguez‐Abreu 14669 9848 1958 3368 183 17.4k
Janis M. Taube 15222 4715 2258 7799 203 20.2k
Scott Antonia 13098 5776 1870 8615 345 20.1k
Alan Sandler 17654 15323 3260 1941 162 23.4k
Naiyer A. Rizvi 10797 7606 2182 2947 274 14.6k
Andreas D. Hartkopf 19125 6723 5424 8923 162 26.7k
Julian R. Molina 10277 7942 3191 1907 211 17.8k
Kim Margolin 10819 5548 2479 5384 308 17.6k
Omid Hamid 20826 4792 1825 9634 407 25.6k

All Works

Loading papers...

Rankless by CCL
2026